Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
KDMF
0
VMF
0
FDF
0
Europe
0
Australia
0
South Africa
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
Annual Reports
NA
1. 6 Alpha-fluoroclobetasol 17-propionate
2. 6-fluoroclobetasol 17-propionate
3. Cgp 14 458
4. Cgp 14458
5. Cgp-14458
6. Halobetasol
7. Ulobetasol
8. Ultravate
1. Ulobetasol Propionate
2. 66852-54-8
3. Ultravate
4. Miracorten
5. Halobetasol (propionate)
6. Bmy-30056
7. Jemdel
8. Cgp-14458
9. Cgp-14,458
10. 91a0k1ty3z
11. Unii-91a0k1ty3z
12. Halobetasol Propionate [usan]
13. Ultravate (tn)
14. Ncgc00167451-01
15. Halobetasol Propionate [usan:usp]
16. [(6s,8s,9r,10s,11s,13s,14s,16s,17r)-17-(2-chloroacetyl)-6,9-difluoro-11-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] Propanoate
17. Bmy 30056
18. Bryhali
19. Halobetasol-propionate
20. Bmy-30056;cgp-14458;ulobetasol Propionate
21. Dsstox_cid_26636
22. Dsstox_rid_81782
23. Dsstox_gsid_46636
24. Schembl33858
25. Halobetasol Propionate (usp)
26. Chembl1200908
27. Dtxsid6046636
28. Chebi:135782
29. Halobetasol Propionate [mi]
30. (6s,8s,9r,10s,11s,13s,14s,16s,17r)-17-(2-chloroacetyl)-6,9-difluoro-11-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3h-cyclopenta[a]phenanthren-17-yl Propionate
31. Hy-b0878
32. Zinc3920028
33. Tox21_112455
34. Mfcd00866013
35. S4089
36. Halobetasol Propionate [vandf]
37. Ulobetasol Propionate [mart.]
38. Akos025310143
39. Ulobetasol Propionate [who-dd]
40. Ccg-269585
41. Cs-4305
42. Halobetasol Propionate [usp-rs]
43. Ncgc00373230-02
44. 21-chloro-6alpha,9-difluoro-11beta,17-dihydroxy-16beta-methylpregna-1,4-diene-3,20-dione 17-propionate
45. Cas-66852-54-8
46. Halobetasol Propionate [orange Book]
47. Halobetasol Propionate [usp Monograph]
48. D04409
49. Duobrii Component Halobetasol Propionate
50. Ab01566925_01
51. Idp-118 Component Halobetasol Propionate
52. 852h548
53. Halobetasol Propionate Component Of Duobrii
54. Sr-01000942239
55. Sr-01000942239-1
56. (6alpha,11beta,16beta)-21-chloro-6,9-difluoro-11-hydroxy-16-methyl-17-(1-oxopropoxy)pregna-1,4-diene-3,20-dione
57. 21-chloro-6.alpha.,9-difluoro-11.beta.,17-dihydroxy-16.beta.-methylpregna-1,4-diene-3,20-dione 17-propionate
58. Pregna-1,4-diene-3,20-dione, 21-chloro-6,9-difluoro-11-hydroxy-16-methyl-17-(1-oxopropoxy)-, (6.alpha.,11.beta.,16.beta.)-
59. Pregna-1,4-diene-3,20-dione, 21-chloro-6,9-difluoro-11-hydroxy-16-methyl-17-(1-oxopropoxy)-, (6alpha,11beta,16beta)-
Molecular Weight | 485.0 g/mol |
---|---|
Molecular Formula | C25H31ClF2O5 |
XLogP3 | 3.7 |
Hydrogen Bond Donor Count | 1 |
Hydrogen Bond Acceptor Count | 7 |
Rotatable Bond Count | 5 |
Exact Mass | 484.1828081 g/mol |
Monoisotopic Mass | 484.1828081 g/mol |
Topological Polar Surface Area | 80.7 Ų |
Heavy Atom Count | 33 |
Formal Charge | 0 |
Complexity | 964 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 9 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
1 of 2 | |
---|---|
Drug Name | Halobetasol propionate |
Drug Label | Halonate Halobetasol Propionate Ointment, 0.05% contains halobetasol propionate, a synthetic corticosteroid for topical dermatological use. The corticosteroids constitute a class of primarily synthetic steroids used topically as an anti-inflammatory... |
Active Ingredient | Halobetasol propionate |
Dosage Form | Ointment; Cream |
Route | Topical |
Strength | 0.05% |
Market Status | Prescription |
Company | Taro; Fougera Pharms; Perrigo; G And W Labs; Perrigo Israel |
2 of 2 | |
---|---|
Drug Name | Halobetasol propionate |
Drug Label | Halonate Halobetasol Propionate Ointment, 0.05% contains halobetasol propionate, a synthetic corticosteroid for topical dermatological use. The corticosteroids constitute a class of primarily synthetic steroids used topically as an anti-inflammatory... |
Active Ingredient | Halobetasol propionate |
Dosage Form | Ointment; Cream |
Route | Topical |
Strength | 0.05% |
Market Status | Prescription |
Company | Taro; Fougera Pharms; Perrigo; G And W Labs; Perrigo Israel |
Vasoconstrictor Agents
Drugs used to cause constriction of the blood vessels. (See all compounds classified as Vasoconstrictor Agents.)
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
A Halobetasol manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Halobetasol, including repackagers and relabelers. The FDA regulates Halobetasol manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Halobetasol API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Halobetasol manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Halobetasol supplier is an individual or a company that provides Halobetasol active pharmaceutical ingredient (API) or Halobetasol finished formulations upon request. The Halobetasol suppliers may include Halobetasol API manufacturers, exporters, distributors and traders.
click here to find a list of Halobetasol suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Halobetasol DMF (Drug Master File) is a document detailing the whole manufacturing process of Halobetasol active pharmaceutical ingredient (API) in detail. Different forms of Halobetasol DMFs exist exist since differing nations have different regulations, such as Halobetasol USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Halobetasol DMF submitted to regulatory agencies in the US is known as a USDMF. Halobetasol USDMF includes data on Halobetasol's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Halobetasol USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Halobetasol suppliers with USDMF on PharmaCompass.
A Halobetasol written confirmation (Halobetasol WC) is an official document issued by a regulatory agency to a Halobetasol manufacturer, verifying that the manufacturing facility of a Halobetasol active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Halobetasol APIs or Halobetasol finished pharmaceutical products to another nation, regulatory agencies frequently require a Halobetasol WC (written confirmation) as part of the regulatory process.
click here to find a list of Halobetasol suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Halobetasol as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Halobetasol API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Halobetasol as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Halobetasol and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Halobetasol NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Halobetasol suppliers with NDC on PharmaCompass.
Halobetasol Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Halobetasol GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Halobetasol GMP manufacturer or Halobetasol GMP API supplier for your needs.
A Halobetasol CoA (Certificate of Analysis) is a formal document that attests to Halobetasol's compliance with Halobetasol specifications and serves as a tool for batch-level quality control.
Halobetasol CoA mostly includes findings from lab analyses of a specific batch. For each Halobetasol CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Halobetasol may be tested according to a variety of international standards, such as European Pharmacopoeia (Halobetasol EP), Halobetasol JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Halobetasol USP).
LOOKING FOR A SUPPLIER?